CENTOGENE

The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE (CNTG) Company Presentation
September 2022

Disclaimer

This presentation has been prepared by CENTOGENE N.V. (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE @ a glance

- Headquarters **Rostock, Germany** with locations in **Boston, MA**, **Berlin, Germany**, and **Rotkreuz, Switzerland**
- ~**400 employees**[1]
- Listed on **Nasdaq** in November 2019 (Ticker: CNTG)

- **FY2021 revenues of €43.5 million**
- Guidance[2] 2022:
  - **Revenues of ~ €50 - €52 million**
    YoY growth 15-20%

- **CENTOGENE Biodatabank**, the **world's largest real-world data repository** for rare and neurodegenerative diseases
- State-of-the-art **genomics and multiomics reference lab** (ISO, CAP, & CLIA certified)



- **>50 collaborations with biotech/biopharma** partners, covering over **46 rare diseases**
- **Market access and expansion**, **clinical development**, **target and drug screening**

1 Based on FTE basis per August 2022, excl. consultants, interns, long-term leavers (maternity, sick leave, …). [2] Guidance as communicated per Q1 2022 earnings announcement. As of Q1 2022, the Company reported COVID-19 testing as discontinued operations. I.e. FY2021 only reflects revenues from the Company's Diagnostics & Pharma segments. The COVID-19 testing business has been exited at the end of Q1 2022.

Essential Life Science Partner in Rare and Neurodegenerative Diseases



CENTOGENE

- Largest Real-World Data Repository for Rare & Neuro Diseases
- Broadest diagnostic testing portfolio for rare diseases
- Accelerate & De-risk from discovery to market access

Insights to 2,500 Rare and Neurodegenerative to Support Breakthrough Therapies



CENTOGENE

- Largest Real-World Data Repository for Rare & Neuro Diseases
- Broadest diagnostic testing portfolio for rare diseases
- Accelerate & De-risk from discovery to market access

The Opportunity: By 2024, 18% of Rx Worldwide Expected to Target Rare Diseases

Significant Need Rare Diseases

- ~350 million people affected by rare genetic diseases, ~90% undiagnosed
- Estimated 80% of ~7,000 rare diseases are genetic in origin: ~5,600[1]
- Public datasets are ~80% of European descent[7]
- <5% of rare diseases have meaningful therapies

Growing Market for Rare Rx

- Rare diseases market expected to grow 11+% to 2024[3]
- By 2024 rare disease products expected ~18% ℞ sales[4]
- FDA have approved 23 gene/cell therapies to date[5]
- >50% of FDA approvals in 2021 were orphan drugs[6]

Stakeholder Pressure to Act

- Regulatory/payor scrutiny raises standards for approval, access and entry
- Patient engagement for new RD, NDD & gene therapies; even with premium priced products
- Stratification and patient profiling can improve labelling, pricing optimization and success

1 Compare Centogene 20-F for FY2021 p. 56 I 2 CENTOGENE Biodatabank statistic per Dec 31, 2021. I 3 & 4 EvaluatePharma – Orphan Drug Report 2020 p. 2 I 5 Based on FDA approvals per May 2022. [Approved Cellular and Gene Therapy Products | FDA] I 6 EvaluatePharma – Orphan Drug Report 2022 p. 2 I 7 The Scientist (2019) "Lack of Diversity in Genetic Datasets is Risky for Treating Disease", reflecting distribution of ancestry of individuals in genome-wide association studies (GWAS) as of January 2019 I * Statements reflect internal management estimates.

Near-term opportunities in addressing key stakeholder challenges

Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Fueling revenues, growing CENTOGENE Biodatabank, and building biopharma partnerships

3 STRATEGIC PILLARS

1 DIAGNOSTICS

Highly differentiated testing portfolio

Easy logistics via CentoCard & CentoCloud

WES/WGS

Multiomics

Network of ~29,000 active physicians

2 CENTOGENE BIODATABANK

Fuel CENTOGENE Biodatabank with biomaterial, multiomics, as well as clinical data

Productize CENTOGENE Biodatabank (data monetization)

3 BIOPHARMA PARTNERSHIPS

MARKET ACCESS & EXPANSION

Real world Registry

Early Access Programs

Patient Stratification, Genetic & Biomarker Profiling, Modelling

Patient Identification & Diagnostics

CLINICAL DEVELOPMENT

Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III:

Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker

Patient Identification & Diagnostic

TARGET & DRUG SCREENING

Patient- derived Cell Models & Multiomics

Biomarker/ Assay Identification & Validation

CENTOGENE BIODATA NETWORK (Insight Reports & Biodata licenses)

CENTOGENE Biodatabank: the world's largest real-world data repository for rare and neurodegenerative diseases



9 Metrics per March 31, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.

The Breadth and Depth of CENTOGENE's Biodatabank make it a Unique Resource

>680,000 individuals
>30,000 via clinical studies

>400,000 biosamples from
>120 countries

Nearly **30,000** active physicians in our network

>2,500 rare diseases diagnosed



High diversity in geographies, ethnicities and patient characteristics

>13k families with trio analysis

>31 million unique variants

High share of pediatric cases

~50% of individuals with broad research consent

Clinical Diagnostics

Market Access & Expansion

Clin. Development Support

Target & Drug Screening

Metrics per March 31, 2022. *Active defined as contact with CENTOGENE within the last 5 years, respectively.

First-in-class Data Capture and Proprietary Curation and Analysis Technologies

Data capture

Gold standard for DNA and multiomic sampling
(from >120 countries

All common forms of sampling accepted
(incl. buccal swab)

Clinical data capture



Clinical data extraction & curation

Whole genome sequencing

State-of-the-art mass spectrometry

RNA sequencing

Data bioinformatics

CENTOGENE BIODATABANK



Automated pipelines for

- variant annotation
- prioritization
- medical reporting
- > 31 million variants
- multiomic analysis and combination expertise

Data utilization

Clinical Diagnostics

Biopharma Partnerships

Target & Drug Screening

Clinical Development Support

Market Access & Expansion

Value chain supported by advanced bioinformatics and AI tools

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Diagnostics: A distinctive offering and services that support efficient and timely diagnosis of rare and neurodegenerative diseases, leading to better treatment and health outcomes

Highly differentiated testing portfolio in state-of-the-art CLIA/CAP certified laboratory with **deep medical expertise**

Exome testing



Genome testing



Multiomic testing

Easy logistics for centralized testing enabling **broad access to multiomics**

Dry-lab (SaaS) solution enabling laboratories around the world to deliver leading diagnostic **insights to local patients**

Unique global footprint with **network of ~29,000 active physicians** and **focus on countries with a high prevalence of rare diseases**

Quality, data integrity & privacy are core to CENTOGENES business processes, driven by first-class data capture, multi-level QMS, & proprietary curation

CENTOGENE follows the strictest quality criteria to meet our customer's requirements in clinical diagnostics, clinical trial services and research & development. CENTOGENE's QMS integrates into every aspect of our operations, from data integrity and privacy, patient safety, and responsibility to scientific research and innovations.

- CENTOGENE's holistic quality management system (QMS) has been recognized by our CAP, CLIA, ISO 15189, and ISO 13485 certifications. CENTOGENE's biobank is the first CAP accredited repository outside the U.S., compliant with ISO 20387
- As a full service company - we follow applicable and market-standard good laboratory practice (GLP) and good manufacturing practice (GMP) guidelines
- We continually participate in the international external proficiency testing schemes of the European Molecular Genetics Quality Network (EMQN) and the College of American Pathologists (CAP) to ensure technical and medical competency and proficiency
- CENTOGENE's processes and IT systems are ISO/IEC 27001:2017 certified by the independent accreditor datenschutz cert GmbH, ensuring a high level of confidentiality, availability, and integrity to all processed data
- CentoPortal is certified for providing safety and privacy according to the "internet privacy standards" by German accreditor datenschutz-cert

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

CLIA ACCREDITATION

Rostock Lab	#8574447 (biorepository)	#99D2049715
Boston Lab	#8417628	#22D2154474

COLLEGE of AMERICAN PATHOLOGISTS
CERTIFICATE OF ISO 15189 ACCREDITATION
CAP # 8005167

Certified Quality System ISO 13485
mdc

Illumina PROPEL certified™
CENTOGENE

ips datenschutz cert GÜTESIEGEL
ISO/IEC 27001 datenschutz cert CERTIFIED

Urkunden-ID: DSC.1096.11.2021
Certificate-ID: DSC.843.09.2020

CENTOGENE Unique Pharma Offering - Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Target & Drug Screening

- Patient-derived Cell Models & Multiomics
- Biomarker/Assay Identification & Validation

Clinical Development

Observational Studies

- Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III

- Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker
- Patient Identification & Diagnostics

Market Access & Expansion

- RW Registry & Early Access Programs
- Patient Stratification, Genetic & Biomarker Profiling, Modelling
- Patient ID & Diagnostics

CENTOGENE Biodata Network

- Insight Reports (e.g., new and existing reports, clinical, genetic, epidemiology)
- Biodata Licenses

Insilico Medicine · evotec · DENALI THERAPEUTICS · alector · agios · Takeda · Pfizer · PTC THERAPEUTICS

Market access and expansion: maximize access and personalise patient, provider and biopharma value

Market Access and Expansion

- Real world registry
- Early access programs

- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling

- Patient Identification
- Patient Diagnostics

- CENTOGENE Biodata Network
  - Insight Reports & Biodata Licenses

Takeda Shire

- **2015 - Ongoing**
- **Rare Metabolic and Rare Neurodegenerative Diseases**
- **Provide diagnostic testing services** to identify patients with **rare metabolic and rare neurodegenerative diseases**
- **42 Countries**

SAREPTA THERAPEUTICS

- **2019 - Ongoing**
- Duchenne muscular dystrophy (DMD)
- **DMD Sponsored testing program (250 samples)**
- **5 countries:** UAE, KSA, Lebanon, Kuwait, Egypt

Pfizer ATTR:INFORMED Genetic testing and counseling for ATTR-CM

- **2015 - Ongoing**
- **Hereditary transthyretin amyloidosis (hATTR) disease**
- Sponsored testing program with > 600 samples from 10 countries (Europe) & 125 samples (U.S.)

PTC THERAPEUTICS REVEAL-CP™

- **2019 - Ongoing**
- Identify patients in **DMD &** Aromatic L-amino Acid Decarboxylase (**AADC)**
- **Genetic testing** and **biomarker analytics** for AADC deficiency in **65 countries** (LATAM, Europe, MENA)
- >2500 DMD & >2900 AADC samples screened

Clinical development: accelerate and expand biopharma partnerships

Clinical Development

Observational studies

- Epidemiology & Patient finding
- Genetic & biomarker profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses

ALEXION AstraZeneca Rare Disease

- **2021**
- **Hypophosphatasia (HPP)**
- Strensiq (innovative enzyme replacement therapy)
- **De novo variant identification** for HPP and **identification of potential new genes** causing HPP
- **Germany**

DENALI THERAPEUTICS

- **2018 - Ongoing** (ROPAD 1 & 2 Study with extensions)
- **Parkinson's disease (PD)**
- **Enroll and genotype 12,500 patients**
- **10 countries**
- Success milestone: **10,000 patients enrolled and genotyped**

Takeda

- **2018 - 2021**
- **Gaucher disease**
- **Longitudinal natural history study** (LysoProof) with **>1,600 samples analyzed**
- **13 countries** (EU, LATAM, APAC, MENA)
- **Identified and genetically tested >250 Gaucher patients**

agios

- **2021 - Ongoing**
- **Pyruvate kinase ("PK") deficiency**
- **Genetic testing and identification of causative mutations**, incl. HBA1, HBA2, and HBB genes, in Ph. II/III trials
- **20 Countries** (North America, Europe, MENA, APAC, & LATAM)

Alnylam PHARMACEUTICALS

- **2020 - Ongoing**
- **Hereditary transthyretin-related amyloidosis (hATTR)**
- **Longitudinal study providing** a **molecular genetic diagnosis of hATTR** via NGS and MLPA
- **Germany**
- **5,000 patients enrolled**

alector

- **2021 - Ongoing**
- Frontotemporal dementia (FTD)
- **Enroll and genetically test over 3,000 FTD patients in EFRONT Study**
- **7 countries** (Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey)

Target & drug screening: build partnerships around precision and confidence

Target and Drug Screening

Target & Drug Screening

- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses

CENTOGENE Insilico Medicine

- **2021 - Ongoing**
- **Niemann-Pick type C**
- **Collaboration to generate data set to enable start of drug discovery**

CENTOGENE evotec

- **2020 - Ongoing**
- **Gaucher Disease – joint drug discovery project**
- **Joint drug discovery project** to identify small molecules reducing **biomarker Lyso-GB1** in disease cell models
- **Transcriptomic** and **metabolomic** data set enabling patient selection with highest unmet need

CENTOGENE

- **2021 - Ongoing**
- **Friedreich's Ataxia, Duchenne Muscular Dystrophy, Hereditary transthyretin-related amyloidosis**
- **Novel biomarker discovery to stratify and monitor patients for disease severity/progression** and to enable the **discovery of disease modifiers** explaining heterogeneity

Pfizer

- **2018 - Ongoing**
- **Rare neurodegenerative diseases**
- **Data Access and Collaboration Agreement granting access** to **CENTOGENE's Biodatabank** for **discovery & validation of novel genetic and biochemical targets** for the potential development of **new therapies for rare diseases**

CENTOGENE 2021 Financials

Core Business - Dx and Biopharma revenues[1]



Record year for Diagnostics

Diagnostics

- Full year 27.9 € million +26% vs FY 2020
- 57,000 test requests +36% vs FY 2020
- WES and WGS ~ 20 € million +25% vs FY 2020

Impacted by COVID

Biopharma

- Full year 15.6 € million -8% vs FY 2020
- Q4 revenues 6.5 € million +40% YoY
- 45 active collaborations by end 2021
- Driven by partnerships in patient identification and clinical development

1. In EUR million, rounded. Core Business defined as revenue from the Diagnostics and Pharma reporting segments.

CENTOGENE Q1 2022 Financials

Dx and Biopharma revenues in € million[1]

Double-digit growth rate

Diagnostics

- Q1 2022 €7.1 million +11% vs Q1 2021
- Q1 2022 16,300 test requests +24% vs Q1 2021
- WES and WGS ~ 3.7 € million +18% vs Q1 2021
- Product portfolio updates on CentoCloud & MOx



Longer recovery post COVID impact

Biopharma

- Q1 2022 € 3.2 million, -10% vs Q1 2021
- Primarily attributable to impact of COVID-19 on slowing pharma programs and longer sales cycle
- 42 active collaborations per March 31, 2022
- Post Q1 2022 extended Agios & Takeda contracts



1 In EUR million, rounded. Revenue from the Diagnostics and Pharma reporting segments; as of Q1 2022, Covid-19-testing is classified as discontinued operations.

CENTOGENE Q1 2022 Financials

P&L and balance sheet highlights in € million[1]

	Q1 2021	Q1 2022	delta
Revenue	**10.0**	**10.3**	*+0.3*
Cost of sales	6.2	6.5	*+0.3*
Gross Profit	**3.8**	**3.9**	*+0.1*
Gross Profit %	*38%*	*38%*	-
Research & development expenses	4.3	4.6	*+0.3*
General Administrative expenses	11.6	7.9	*(3.7)*
Selling expenses	1.9	2.4	*+0.5*
Impairment of financial assets	0.1	0.2	*+0.1*
Other operating income	0.4	0.7	*+0.3*
Other operating expenses	0.0	0.0	-
Operating loss	**(13.9)**	**(10.5)**	*+3.4*

Balance sheet highlights
(in € million)

	Q1 2022	Q4 2021	delta
Cash & cash equivalents	42.7	17.8	24.8
Debt outstanding[2]	(43.0)	(22.5)	(20.5)
Net debt	(0.3)	(4.7)	4.4

1 Selected information, may include rounding differences

2 Debt outstanding includes non-current loans, non-current lease liabilities, current loans and current lease liabilities.

CENTOGENE Guidance: 2022 poised for post-COVID recovery and refocus on core business and growth strategy

Core Business - Dx and Biopharma revenues[1]



FY 2022 Guidance[2]

Dx & Pharma revenue growth to ~50-52 € million

+15-20% YoY

- **$62 million financing (~€55 million)** announced Q1 2022:
  - €15 million PIPE & $45 million debt [3]
- Q1 of € 10.3 million up 3% year-over-year - acceleration in second half driven by biopharma
- Q1 COVID-19 revenues of ~€19 million; exited in **Q1 2022**[4]

1. In EUR million, rounded. Revenues reflect the Diagnostics and Pharma reporting segments, and do not include the COVID-19 Testing revenues recorded in the period 2020 – Q1 2022. COVID-19 Testing has been reported as discontinued operations since Q1 2022. I 2. Guidance as communicated per Q1 2022 earnings announcement. I 3. CENTOGENE announced the closing of a € 15 million (~$ 17 million) private placement financing incl. warrants as well as the entry into a USD 45 million senior secured loan facility on February 1, 2022. I 4. Reported as discontinued operations as of Q1 2022.

Near and Mid Term Priorities

Topline

Growth

- Focus on unique and transformative business model
- Expand pharma partnerships
  - Fully execute on our existing >20 ongoing partnerships and target ~20+ new pipeline deals
- Keep growing Dx at above-market level
  - Focus on profitable growth
  - Commercial excellence, CentoCloud & multiomics

2022 Guidance:*

Revenues

~50-52 € million

+15-20% YoY

Bottomline

Cost management

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Q1 2022

€ 10.3M up +3% yoy acceleration in 2H22 driven by biopharma

Runway

Cashflow

- Sector is not about growth at all costs
- Diligently manage cash and extend runway

$62M financing (~€55M) in Q1 2022: €15M PIPE & $45M secured debt facility **

* Revenues reflect the Diagnostics and Pharma reporting segments, and do not include the COVID-19 Testing revenues recorded in the period 2020 – Q1 2022. COVID-19 Testing has been reported as discontinued operations since Q1 2022. Guidance as communicated per Q1 2022 earnings announcement. ** CENTOGENE announced the closing of a € 15 million (~$ 17 million) private placement financing incl. warrants as well as the entry into a USD 45 million senior secured loan facility on February 1, 2022. / Image source: flaticon.com

CENTOGENE
THE RARE DISEASE COMPANY

Thank you